Repagermanium

DRUG2 trials

Sponsors

Dimerix Bioscience Pty Limited, University of Sydney

Conditions

COVID-19Focal segmental glomerulosclerosisSARS-CoV2 Infection

Phase 2

Controlled Trial of Angiotensin Receptor Blocker (ARB) & Chemokine Receptor Type 2 (CCR2) Antagonist for the Treatment of COVID-19

TerminatedNCT05122182

University of SydneyCOVID-19, SARS-CoV2 Infection

Start: 2022-01-07End: 2023-01-28Updated: 2023-09-15

Phase 3

A pivotal Phase 3, multicenter, randomized, double-blind, placebo-controlled study of the efficacy and safety of DMX-200 in patients with focal segmental glomerulosclerosis (FSGS) who are receiving an angiotensin II receptor blocker (ARB)

Active, not recruitingCTIS2023-504597-37-00

Dimerix Bioscience Pty LimitedFocal segmental glomerulosclerosis

Start: 2022-03-25Target: 95Updated: 2026-01-19

Related Papers

Combination of the chemokine receptor type 2 (CCR2) antagonist DMX-200 and candesartan for COVID-19: a randomised controlled trial

BMJ Open2024-10-01